Trials / Completed
CompletedNCT07222423
A Study of the Epidemiology and Hospital Management of Patients With PROS in France
Epidemiology and Hospital Management of Patients With PROS in France: a PMSI Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 3,605 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 2 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study was to estimate the incidence and prevalence of a group of genetic disorders known as PIK3CA-Related Overgrowth Spectrum (PROS) in France. Additionally, the study aimed to characterize patients, disease management, and costs associated with PROS. This study used data from the French National Hospitals Database, Programme de Médicalisation des Systèmes d'Information (PMSI). The study period was from January 2015 to December 2022.
Conditions
Timeline
- Start date
- 2024-01-15
- Primary completion
- 2024-10-08
- Completion
- 2024-10-08
- First posted
- 2025-10-29
- Last updated
- 2025-10-29
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT07222423. Inclusion in this directory is not an endorsement.